GlassScriptPhysician profile
Jeffrey R Peterman
NPI 1184712432
$4,153.33
in general payments reported to CMS, 2019-2025
27 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $783 · 2021: $585 · 2022: $479 · 2023: $616 · 2024: $58.04 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.83 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $553.49 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $449.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $413.09 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.75 | 2019-2025 | Jardiance, Synjardy |
| Horizon Therapeutics Plc | $267.43 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $210.12 | 2019-2021 | |
| Glaxosmithkline, LLC. | $208.73 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $205.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $203.92 | 2019-2022 | |
| Astellas Pharma US INC | $171.74 | 2019-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $162.63 | 2019-2022 | |
| Abbvie INC. | $145.97 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $127.49 | 2019-2020 | |
| Lilly USA, LLC | $121.50 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $115.59 | 2021-2023 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $92.27 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $76.15 | 2019-2023 | Eliquis |
| Radius Health, INC. | $60.46 | 2019 | |
| Axsome Therapeutics, INC. | $47.61 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $39.57 | 2019 | |
| Esperion Therapeutics, INC. | $39.56 | 2020-2021 | |
| Dexcom, INC. | $31.97 | 2021 | |
| Neurocrine Biosciences, INC. | $20.75 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.07 | 2025 | Caplyta |
| Lundbeck LLC | $14.69 | 2023 | Rexulti |
| Allergan, INC. | $12.90 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Peterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.